Scarica l'app Stockscreener
20.80
3.38%
0.68
Dopo l'orario di chiusura:
20.78
-0.02
-0.10%
Precedente Chiudi:
$20.12
Aprire:
$20.25
Volume 24 ore:
397.45K
Relative Volume:
1.10
Capitalizzazione di mercato:
$858.65M
Reddito:
-
Utile/perdita netta:
$-136.98M
Rapporto P/E:
-5.1741
EPS:
-4.02
Flusso di cassa netto:
$-126.63M
1 W Prestazione:
-5.33%
1M Prestazione:
+0.24%
6M Prestazione:
-1.42%
1 anno Prestazione:
-24.28%
Intervallo 1D:
$20.01
$21.01
Intervallo di 1 settimana:
$20.01
$22.42
Portata 52W:
$15.47
$29.71
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Confronta AVBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.80 | 830.58M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Iniziato | BTIG Research | Buy |
| 2025-11-25 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-03-20 | Iniziato | B. Riley Securities | Buy |
| 2025-03-10 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-20 | Iniziato | Citigroup | Buy |
| 2024-02-20 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | Jefferies | Buy |
Mostra tutto
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha
Firmonertinib Trial Aims to Crack a Long-Standing Lung Cancer Treatment Gap - MyChesCo
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2%What's Next? - MarketBeat
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug - Investing.com Australia
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating - Investing.com
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study - TipRanks
ArriVent BioPharma Begins Phase 3 Trial of Firmonertinib in Lung Cancer - marketscreener.com
ArriVent BioPharma Initiates Pivotal Phase 3 ALPACCA Study of Firmonertinib for First-Line Treatment of EGFR PACC Mutant NSCLC - Quiver Quantitative
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug By Investing.com - Investing.com South Africa
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - marketscreener.com
New lung cancer trial tests a daily chemo-free pill for rare mutation - Stock Titan
Investment Recap: Will ArriVent BioPharma Inc. stock benefit from AI adoptionLong Setup & Daily Profit Maximizing Tips - Улправда
Will ArriVent BioPharma Inc. stock benefit from AI adoptionQuarterly Portfolio Review & Free AI Powered Buy and Sell Recommendations - Улправда
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will ArriVent BioPharma Inc. stock pay special dividendsTrade Volume Summary & Low Drawdown Investment Strategies - ulpravda.ru
Will ArriVent BioPharma Inc. stock remain a Wall Street favorite2025 Technical Overview & Real-Time Buy Zone Alerts - Улправда
Why ArriVent BioPharma Inc. stock is recommended by analystsMarket Trend Summary & Weekly Breakout Watchlists - Улправда
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6%Here's What Happened - MarketBeat
Will ArriVent BioPharma Inc. stock deliver consistent dividendsJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - Улправда
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (2025-12-16) - Seeking Alpha
Squarepoint Ops LLC Grows Stock Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma Earnings Notes - Trefis
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential - MSN
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BTIG Research Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Inc (AVBP) is looking forward to a strong quarter - setenews.com
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at BTIG Research - MarketBeat
BTIG initiates coverage of ArriVent BioPharma (AVBP) with buy recommendation - MSN
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential - Investing.com Canada
ArriVent Biopharma initiated with a Buy at BTIG - TipRanks
BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) versus Sunshine Biopharma (NASDAQ:SBFM) Critical Review - Defense World
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment - TipRanks
Is ArriVent BioPharma Inc (AVBP) positioned for future growth? - Setenews
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.4%Here's What Happened - MarketBeat
Understanding Momentum Shifts in (AVBP) - Stock Traders Daily
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MSN
How ArriVent BioPharma Inc. stock trades before earnings2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Will ArriVent BioPharma Inc. stock sustain high P E ratiosWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
A new trading data show ArriVent BioPharma Inc (AVBP) is showing positive returns. - Setenews
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Initiates Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent Biopharma initiated with a Buy at Truist - TipRanks
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug - Investing.com Canada
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):